Arthur LC
@as130888
Interested in lung cancer news and research and healthcare policy more generally
Good news for our friends @EGFRResisters —Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC onclive.com/view/sacituzum…
Palliative surgery is effective in patients with EGFR-mutant lung adenocarcinoma with pleural metastasis tlcr.amegroups.org/article/view/9…
The highlight of my 7 yr advocacy journey since my early stage lobectomy surgery is traveling w/ @leahlphillips to @IASLC #WCLC24 knowing she is now able to receive surgery for HER stage IV disease! THIS IS HOPE! @lungoncdoc @maraantonoff @YoungLungCancer @breathofhopeky
Our September newsletter is out now!Read about latest research, clinical trial updates, educational events, and meet Karen Bonte, who shares her lung cancer journey in our new Members Spotlight. mailchi.mp/d9891e8b1254/s…
What wonderful news for our #HER2 Heroes in the Exon 20 Group that zongertinib now has BTD for #NSCLC #HER2 (#ERBB2) #Exon20-mutated lung cancer. Congratulations to all zongertinib principal investigators, study teams, patients, care partners, & family members! And…
This is the second BTD for HER2-mut NSCLC, together with BAY88 @Bayer , offering hope to patients! @Exon20Group @EGFRResisters @lungoncdoc FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC targetedonc.com/view/fda-grant… via @targetedonc
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of #LungCancer and Other Malignancies Targetable with MET Inhibitors. bit.ly/4cFiu18 @pecci_federica1, Seshiru Nakazawa, Pasi Janne, @DrMarkAwad and colleagues. @DanaFarber
Phase III KEYNOTE 789 results @JCO_ASCO: platinum + pemetrexed + pembrolizumab vs placebo in #EGFR NSCLC post TKI (n=492). Adding pembro did not improve outcomes (PFS 5.6m vs 5.5m, HR 0.80; OS 15.9m vs 14.7m, HR 0.84) and added toxicity. ascopubs.org/doi/10.1200/JC…
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) - JTO Clinical and Research Reports jtocrr.org/article/S2666-….
This is what progress looks like! It’s a big day for our #lungcancer community, bringing new light & determination to our journey 💜 #LCSM
World-first lung cancer vaccine trials launched across seven countries dlvr.it/TCGLVl
The @UVACancerCenter is the first healthcare provider in Virginia to offer a newly approved immunotherapy that supercharges the body’s immune system to treat small cell lung cancer. @ryangentzler @rdhalljr bit.ly/3MeOv5w
Sorry one more since the last poll for #LCSM wasn’t helpful for all options (dang word limits). For newly dx stage 4 EGFRm+ pt, with high risk features (brain mets, comutations, high dz burden), assuming all available to you:
Online First: Efficacy and safety of #immunecheckpointinhibitors for individuals with advanced EGFR-mutated non-small-cell #lungcancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis thelancet.com/journals/lanon…
In the Clinic: Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations ascopost.com/issues/july-25… #LCSM #lungcancer #oncology
LAURA phase III trial: Osimertinib demonstrates statistically significant PFS benefit in patients with unresectable stage III EGFR-mutated #NSCLC following chemoradiotherapy. bit.ly/4aJH53U #ASCO24 @SureshRam_EM
A multidisciplinary CU Cancer Center team helped Jimmy Guerrero battle two types of cancer after he initially struggled to get a diagnosis. Read Guerrero's cancer story ⬇️ news.cuanschutz.edu/cancer-center/…
With the increased use of TKIs in the management of #EGFR mutant #NSCLC, transformation to #SCLC as a resistance mechanism is likely underdiagnosed. Tissue Bx needed but a liquid approach may complement. #LCSM @EGFRResisters
SCLC transformation in #EGFR mutant NSCLC likely underdiagnosed - requires tissue biopsy but can liquid biopsy help? Novel epigenomic cfDNA approach @CCR_AACR shows uses histone modification to distinguish histologies. Very promising approach! aacrjournals.org/clincancerres/…
LCRF's CSO, Dr. Toni Wozniak, discusses what the results of the CROWN study might mean for patients. The study was presented at this year's ASCO annual meeting. #ScienceMadeSimple #ASCO24 LCRF.org/SMS071624
Great to see this new updated guideline on oncogene-addicted metastatic NSCLC from @myESMO
📣 The new ESMO Living Guideline on Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer is now online. 🔗 ow.ly/aWHx50SBy3O
Impact of #ALK fusion variants @JTOonline. The specific fusion breakpoint has a profound impact. Variant 1 accounts for 50%, with TTD 20.3m whereas variant 3 accounts for 36% and TTD only 11.5m. Variant 3 plus TP53 co-mutation had TTD of only 7.4m. jto.org/article/S1556-…
With great sadness, we share that Laura Greco passed away over the weekend. The #LungCancer community has lost a champion, and we extend our condolences to all who loved her. Learn more about Laura and read the profile we published on our website in 2022. LCRF.org/laura